Adaptin Bio (APTN) Free Cash Flow (2023 - 2026)

Adaptin Bio has disclosed Free Cash Flow across 4 years of filings, most recently posting -$596298.0 for Q1 2026.

• Quarterly Free Cash Flow rose 73.85% year-over-year to -$596298.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.1 million (down 8.98% YoY) and the FY2025 annual result came in at -$4.8 million, down 635.87% from the prior year.
• Free Cash Flow advanced to -$596298.0 in Q1 2026, from -$702876.0 in the prior quarter.
• Across five years, Free Cash Flow topped out at $112653.0 in Q4 2024 and bottomed at -$2.3 million in Q1 2025.
• The 4-year median for Free Cash Flow is -$532357.0 (2024), against an average of -$608182.0.
• Year-over-year, Free Cash Flow jumped 293.07% in 2024 and plunged 2441.81% in 2025.
• Adaptin Bio's Free Cash Flow stood at -$58347.0 in 2023, then jumped by 293.07% to $112653.0 in 2024, then tumbled by 723.93% to -$702876.0 in 2025, then rose by 15.16% to -$596298.0 in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$596298.0, -$702876.0, and -$772430.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.